24/7 Market News Snapshot 16 July, 2025 – OKYO Pharma Limited Ordinary Shares (NASDAQ:OKYO)
DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (NASDAQ:OKYO) are discussed in this article.
OKYO Pharma Limited is currently witnessing a notable fluctuation in its stock performance, with ordinary shares opening at $2.83 but recently trading at $2.545, marking a decline of approximately 7.45%. This downturn follows a previous session close of $2.750 and points to a potential bearish sentiment among investors, likely triggered by profit-taking or concerns surrounding the company’s near-term outlook. Current trading volume is reported at 759.45K, indicating significant market activity. Analysts are advised to monitor key support levels around $2.50; a breach could invite further selling pressure, while a rebound above $2.75 may signal a revival in bullish momentum. Upcoming news and earnings reports will be pivotal in shaping market sentiment.
Simultaneously, OKYO Pharma has made substantial strides in its development of Urgosimod, a novel treatment aimed at neuropathic corneal pain (NCP). Preliminary results from a Phase 2 clinical trial involving 18 participants reveal that 75% of those treated with a 0.05% formulation of Urgosimod experienced over an 80% reduction in pain, as measured by Visual Analogue Scale (VAS) scores. This advancement is particularly significant given the absence of an FDA-approved therapy for NCP.
The randomized, double-masked, placebo-controlled trial exhibited statistically significant reductions in pain scores, with improvements evident as early as Week 4 and maintained through the study duration. Dr. Pedram Hamrah, the principal investigator, emphasized the implications of these findings, indicating a breakthrough treatment for individuals suffering from moderate to severe NCP.
Dr. Gary S. Jacob, CEO of OKYO, praised the trial outcomes and underscored the company’s commitment to bringing Urgosimod to market. Plans are underway for a discussion with the FDA regarding the next steps, marking a strategic move in advancing clinical development to address this critical medical need effectively. The growing interest in Urgosimod positions OKYO as a frontrunner in developing effective therapies for chronic neuropathic pain.